Colibri Group (“Colibri”), a professional education company with leading brands that provide learning solutions to licensed professionals, announces today that the company has acquired TRC Healthcare. With the addition of…
Prospection—the pioneer of patient-centric intelligence—today announced the availability of Prospection AI, its self-service patient-centric intelligence (PCI) platform designed to save life sciences commercial organizations time and money by unlocking insights into…
Nanjing IASO Biotechnology Co., Ltd. (IASO Bio) made its debut at the 6th China International Import Expo (CIIE) with FUCASO, the world’s first fully-human CAR-T, and entered into a strategic partnership…
AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca…
OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke is being stopped early. This decision is…
The “Diagnostic Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering. This report contains a comprehensive listing of 2087 diagnostic deals announced since 2016 including financial terms where available including links…
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced positive results from its…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the Elecsys®Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for the detection of hepatitis E virus (HEV) infections in countries…
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or…
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022. Kite has exercised its…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a…